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Increased glycogen synthase kinase-3 (GSK-3) activity is
believed to contribute to the etiology of chronic disorders
like Alzheimer’s disease and diabetes, thus supporting
therapeutic potential of GSK-3 inhibitors. However, sus-
tained GSK-3 inhibition might induce tumorigenesis
through b-catenin-APC dysregulation. Besides, sustained
in vivo inhibition by genetic means (constitutive knock-
out mice) revealed unexpected embryonic lethality due to
massive hepatocyte apoptosis. Here, we have generated
transgenic mice with conditional (tetracycline system)
expression of dominant-negative-GSK-3 as an alternative
genetic approach to predict the outcome of chronic GSK-3
inhibition, either per se, or in combination with mouse
models of disease. By choosing a postnatal neuron-speciﬁc
promoter, here we speciﬁcally address the neurological
consequences. Tet/DN-GSK-3 mice showed increased neu-
ronal apoptosis and impaired motor coordination.
Interestingly, DN-GSK-3 expression shut-down restored
normal GSK-3 activity and re-established normal inci-
dence of apoptosis and motor coordination. These results
reveal the importance of intact GSK-3 activity for adult
neuron viability and physiology and warn of potential
neurological toxicity of GSK-3 pharmacological inhibition
beyond physiological levels. Interestingly, the reversibility
data also suggest that unwanted side effects are likely to
revert if excessive GSK-3 inhibition is halted.
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Introduction
Glycogen synthase kinase-3 (GSK-3) is a serine/threonine
kinase that is present in most tissues and that is particularly
abundant in the central nervous system (CNS) (Woodgett,
1990). There are two isoforms of the enzyme termed GSK-3a
and GSK-3b that are encoded by two different genes
(Woodgett, 1990). GSK-3 is known to participate in multiple
signaling pathways coupled to receptors for a variety of
signaling molecules such as insulin or wnt among many
others (Jope and Johnson, 2004). Regulation of GSK-3 is
characterized by the fact that the enzyme is active in resting
conditions with activation of the different signaling path-
ways, leading to GSK-3 inhibition by its phosphorylation on
the Ser21 or Ser9 residue of GSK-3a and GSK-3b, respectively
(Grimes and Jope, 2001). GSK-3 phosphorylation substrates
include cytoskeletal proteins, transcription factors, and meta-
bolic regulators, thus leading to a prominent role of GSK-3 in
cellular architecture, gene expression, cell division and fate
decision, and apoptosis among others (Grimes and Jope,
2001; Jope and Johnson, 2004).
Aberrantly increased GSK-3 activity is believed to play a key
role in the pathogenesis of chronic metabolic disorders like
type-II diabetes (Eldar-Finkelman, 2002), as well as of CNS
conditions such as mood disorders and Alzheimer’s disease
(Avila et al, 2004; Jope and Johnson, 2004). With regard to
GSK-3 and neurodegeneration, increased GSK-3 activity has
been reported to result in neuronal apoptosis and GSK-3
inhibitors have been shown to exert antiapoptotic and neuro-
protective effects in many different cell and mouse models (Pap
and Cooper, 1998; Hetman et al, 2000; Beurel and Jope, 2006).
Accordingly, potent and speciﬁc GSK-3 inhibitors are currently
under development in view of their therapeutic potential
(Cohen and Goedert, 2004; Frame and Zheleva, 2006; Gould
et al, 2006). However, there are two main concerns that
counteract the predicted usefulness of GSK-3 inhibitor thera-
pies. On the one hand, the prominent role of GSK-3 in the
adenomatous polyposis coli (APC)–b-catenin destruction com-
plex implies that inhibition of GSK-3 could possibly lead to
tumor promotion through the activation of b-catenin (Polakis,
2000). On the other hand, despite the above mentioned pre-
dicted antiapoptotic effect of GSK-3 inhibition, in vivo sustained
inhibition by genetic means (constitutive knock-out mice)
revealed an unexpected embryonic lethality due to massive
hepatocyte apoptosis (Hoeﬂich et al, 2000). In this regard,
pharmacological inhibition of GSK-3 in cell lines has also
been shown to facilitate apoptosis triggered by certain stimuli
(Beyaert et al, 1989; Song et al, 2004; Beurel and Jope, 2006).
In order to explore the consequences of sustained
GSK-3 inhibition in adult tissues, here we have generated
transgenic mice carrying a transgene encoding a dominant
negative (DN) form of GSK-3b (DN-GSK-3) under control of
Received: 21 November 2006; accepted: 24 April 2007; published
online: 17 May 2007
*Corresponding author. Centro de Biologı´a Molecular ‘Severo Ochoa’,
CSIC/UAM, Campus UAM de Cantoblanco, Madrid 28049, Spain.
Tel.: þ 34 91 497 3595/8073; Fax: þ 34 91 497 8087;
E-mail: jjlucas@cbm.uam.es
The EMBO Journal (2007) 26, 2743–2754 | & 2007 European Molecular Biology Organization |All Rights Reserved 0261-4189/07
www.embojournal.org
&2007 European Molecular Biology Organization The EMBO Journal VOL 26 | NO 11 | 2007
 
EMBO
 
THE
JOURNAL
2743
a tetracycline-controlled conditional promoter. Due to the
binary nature of the conditional transgenic system, these
mice become a powerful tool because transgene transactiva-
tion can be directed to different tissues upon crossing with
any of the available driver mice that express tTA (Tet-Off)
under control of different promoters (Lewandoski, 2001).
To speciﬁcally address the neurological consequences of a
sustained decrease in GSK-3 activity, we used driver mice
with postnatal neuron-speciﬁc expression (CamKII-tTA mice;
Mayford et al, 1996). Here, we report that sustained expres-
sion of DN-GSK-3 in the resulting double transgenic mice
(Tet/DN-GSK-3 mice) leads to decreased GSK-3 activity and
concomitant decreased phosphorylation of the microtubule-
associated protein tau, a well-characterized GSK-3 substrate.
Interestingly, Tet/DN-GSK-3 mice grew normally and no
evidence of tumor formation was obtained either after gross
anatomical examination or after analysis of brain morphol-
ogy. However, apoptosis was detected in Tet/DN-GSK-3 mice
in brain regions involved in motor control. Accordingly, Tet/
DN-GSK-3 mice also showed a behavioral deﬁcit in motor
coordination. Finally, DN-GSK-3 transgene shutdown by dox-
ycycline administration resulted in normal GSK-3 activity and
in full reversal of the motor and of the neuronal apoptosis
phenotypes.
Results
Mouse design
Constitutive knock-out of GSK-3b in mice is known to result
in embryonic lethality (Hoeﬂich et al, 2000). As an alternative
genetic approach to explore the consequences of a sustained
decrease in GSK-3 activity in adult tissues, we decided to
generate mice with conditional transgenic expression of a
dominant-negative (DN) form of GSK-3. More precisely, the
K85R mutant form of GSK-3b (DN-GSK-3) was chosen in view
of its previously shown efﬁcacy in decreasing GSK-3 activity
(Dominguez et al, 1995).
The tetracycline-regulated system can be used for condi-
tional gene expression in mice (Gingrich and Roder, 1998;
Lewandoski, 2001). By using this system, we have previously
generated inducible mouse models of neurodegenerative dis-
eases (Yamamoto et al, 2000; Lucas et al, 2001). Similarly,
here we decided to generate mice with the DN-GSK-3 trans-
gene linked to a tetracycline responsive (tetO) promoter
(Figure 1A). These mice can then be bred with mice with
tissue-speciﬁc expression of the tetracycline transactivator
(tTA, also known as Tet-Off). Then, double transgenic mice
will express DN-GSK-3 in a tetracycline-repressible manner
(Figure 1B). There are many available mouse lines expressing
tTA (Lewandoski, 2001). Here, we aimed to explore the
neurological consequences of sustained GSK-3 inhibition by
using mice that express tTA under control of a postnatal
neuron-speciﬁc promoter (Cam-KII-tTA mice; Mayford et al,
1996).
To generate the DN-GSK-3 construct for transgenesis, the
sequence of the K85R mutant form of GSK-3b was cloned into
a cassette containing the bidirectional tetO (Bi-tetO) promoter
linked to a b-galactosidase (b-gal) reporter in divergent
orientation (Figure 1A). Our previous experience in generat-
ing conditional transgenic mice with the tet-regulated system
indicates that the site of insertion and/or the copy number
of the tetO construct inﬂuences the ﬁnal pattern and level of
transactivation by tTA (Yamamoto et al, 2000; Lucas et al,
2001). The b-gal reporter sequence in the DN-GSK-3 construct
permits, on one hand, a quick analysis of the pattern of trans-
gene expression in the double transgenic (Tet/DN-GSK-3)
mice from the different founder lines by X-gal staining or
by immunohistochemistry against b-gal. On the other hand,
it also allows to test the efﬁciency of transgene silencing
after tetracycline administration (Yamamoto et al, 2000;
Diaz-Hernandez et al, 2005; Engel et al, 2006).
Generation of mice with conditional expression
of DN-GSK-3 in forebrain neurons
Four independent transgenic mouse founder lines were ob-
tained that carried the DN-GSK-3 construct and they were
termed R1, R2, R3 and R4 (Figure 1B). To study the effect of
sustained GSK-3 inhibition in adult neurons, these mouse
lines were then bred with the Cam-KII-tTA mouse line. In
good agreement with the postnatal nature of the driver
neuronal promoter, the percentage of double transgenic
mice was close to the expected 25% for all founder lines
(R1: 29/151, R2: 56/177, R3: 37/167, R4: 54/200 in the ﬁrst
analyzed litters).
The level and pattern of expression of the reporter trans-
gene b-gal was then analyzed in 2-month-old Tet/DN-GSK-3
mice by Western blot and by immunohistochemistry. Tet/
DN-GSK-3 mice resulting from line R3 showed the lowest level of
transactivation by Western blot (Figure 1C) and, as evidenced
by immunohistochemistry, this was restricted to the ventral
striatum (data not shown). Lines R1, R2 and R4, on the other
hand, led to b-gal expression in a spatial pattern very similar
to that of endogenous CamKIIa, with expression evident in
cortex, hippocampus, striatum, amygdala, and olfactory bulb
neurons (Figure 1C–F and data not shown). Since CamKIIa is
known to be expressed to a lesser extent in spinal cord (Liang
et al, 2004), we also analyzed this structure, but no expres-
sion was detected either by Western blot, immunohistochem-
istry, or X-Gal staining (Supplementary Figure 1). Similarly
and as expected, no transgene expression was detected in
other brain regions with no expression of CamKIIa, such as
cerebellum, brainstem, or thalamus nor in peripheral tissues
(Supplementary Figure 1 and data not shown). Expression
was highest in the striatum, where the vast majority of
neurons showed transgene expression (Figure 1C and D).
On the other hand, in the cortex and in the hippocampus,
expression was restricted to certain neuronal subpopulations
(Figure 1E and F). More precisely, cortical expression was
located mainly in layer II–III neurons and hippocampal
expression was essentially restricted to neurons in the CA1
ﬁeld. In good agreement with the b-gal immunohistochem-
istry data, striatum was the only analyzed brain region,
where increased total GSK-3b (endogenous plus transgenic
DN-GSK-3b; 0.9 fold increase, Po0.05) was detected by
Western blot (Figure 2A), and where some neurons expressed
DN-GSK-3b above threshold for detection by immunoﬂuor-
escence with anti-myc antibody (data not shown). Since R1,
R2, and R4 Tet/DN-GSK-3 mice gave a similar pattern and
level of transactivation, the three lines were analyzed in
parallel. For all the biochemical, histological, and behavioral
determinations, the three lines exhibited very similar pheno-
types and we will refer to them indistinguishably as Tet/
DN-GSK-3 mice.
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Tet/DN-GSK-3 mice grew normally and they showed no
differences in body weight with respect to their wild-type litter-
mates. Tet/DN-GSK-3 mice also showed a normal lifespan and no
evidence of tumor formation was obtained either after gross
anatomical examination or after analysis of brain morphology.
Reduced GSK-3 activity in the striatum of Tet/DN-GSK-3
mice
To verify that the forebrain expression of DN-GSK-3 resulted
in decreased GSK-3 activity, we performed GSK-3 enzymatic
activity assays on brain lysates as well as Western
blot determination of the phosphorylated forms of GSK-3
and of its well-established substrate tau. In good agreement
with the fact that striatum was the brain region with the
highest level of transgene expression, GSK-3 activity
was signiﬁcantly reduced on striatal homogenates of Tet/
DN-GSK-3 mice compared with those of wild-type mice
(Figure 2B). A tendency toward decreased activity was ob-
served also in cortical and hippocampal homogenates, but
this did not reach statistical signiﬁcance (Figure 2B).
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Figure 1 Generation of Tet/DN-GSK-3 mice and mapping of transgene expression. (A) Diagram showing the structure of the DN-GSK-3
construct used for transgenesis. The bidirectional Bi-tetO promoter is followed in one direction by the K85R-GSK-3b (DN-GSK-3) cDNA
sequence with a myc epitope, and by the b-galactosidase (b-gal) sequence with a nuclear localization signal (NLS) in the other direction.
(B) Generation of the conditional transgenic Tet/DN-GSK-3 mice (lines 1–4) by breeding the four DN-GSK-3 founder mice (R1, R2, R3 and R4
mice) with mice expressing tTA under control of the CamKIIa promoter (tTA mice). (C) Western blot detection of b-gal in striatum, cortex and
hippocampus of 2-month-old Tet/DN-GSK-3 (R1, R2, R3 or R4) mice and control mice. (D–F) b-gal immunohistochemistry on sagittal brain
sections from a 2-month-old Tet/DN-GSK-3 mouse (line 2). (D) striatum, (E) cortex and (F) hippocampus. ac, anterior commisure; Cx, cortex,
I–VI, cortical layers; cc, corpus callosum; DG, dentate gyrus. Scale bar in panel E corresponds to 300 mm in panels (E, F), and to 200mm in
panel (D).
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Similarly, no decrease was observed in non-expressing brain
regions such as cerebellum.
We then analyzed by Western blot the striatal level of the
inactive forms of GSK-3 that results from phosphorylation on
Ser9 of the b isoform and on Ser21 of the a isoform (p-GSK-3)
(Figure 2A). Interestingly, expression of DN-GSK-3b resulted
in a dramatic increase (3.2-fold, Po0.001) not only in phos-
pho-Ser9-GSK-3b but also in phospho-Ser21-GSK-3a. Since
total GSK-3a levels are not altered in Tet/DN-GSK-3 mice
(data not shown), this strongly suggests that the observed net
reduction in GSK-3 activity is probably due in part to the
previously reported mechanism that ampliﬁes GSK-3 inhibi-
tion (Jope, 2003; Zhang et al, 2003). This mechanism is based
on increased phosphorylation at the Ser21/9 residues in
response to sustained inhibition of GSK-3 either by pharma-
cological or genetic means, even if the latter is performed in a
single isoform (e.g. GSK-3b knock-out ﬁbroblasts; Hoeﬂich
et al, 2000). A moderate increase in the levels of inactive
Ser21/9 phospho-GSK-3 was also observed by Western blot in
the other two analyzed transgene expressing brain regions,
hippocampus, and cortex. However, as for the GSK-3 activity
assay data, the cortical and hippocampal increases in Ser21/9
phospho-GSK-3 did not reach statistical signiﬁcance after
normalizing for total GSK-3 levels (data not shown). In
good agreement with the marked striatal decrease in GSK-3
activity, the level of phosphorylation of tau was reduced in
striatal homogenates of Tet/DN-GSK-3 mice. This was evi-
denced by Western blot with the AT-8 (72% reduction,
Po0.01) and the PHF-1 (46% reduction, Po0.01), antibodies
(Figure 2A) that recognize two independent phospho-epi-
topes that are known to be phosphorylated by GSK-3
(Lovestone et al, 1994). We also analyzed the level of
b-catenin that is also a GSK-3 substrate. Since b-catenin
phosphorylation by GSK-3 favors its degradation by the
proteasome (Aberle et al, 1997), we reasoned that its levels
might be increased in Tet/DN-GSK-3 mice. However, as
shown in Figure 2A, b-catenin levels were not changed in
these mice.
We then explored by immunoﬂuorescence the tissue dis-
tribution of the detected decrease in tau phosphorylation
(Supplementary Figure 2). As expected, given the axonal
localization of tau, the decrease in phospho-tau staining
occurs diffusely throughout the striatal neurophil. This
strongly suggests that the decrease takes place predominantly
in the axons of medium size spiny neurons, that represent
more than 90% of the neurons in the striatum (see staining
with the DARPP-32 marker in Supplementary Figure 2B and
E) and that have long axons that project outside the striatum.
However, the somas of few large interneurons were also
detected by PHF-1 immunoﬂuorescence and the intensity of
this staining was diminished in Tet/DN-GSK-3 mice
(Supplementary Figure 2A, D, G, and I). By double labeling
immunoﬂuorescence we were able to identify these neurons
as a subset of the choline acetyltransferase (ChAT)-positive
large interneurons (Supplementary Figure 2G–J). In sum-
mary, decreased tau phosphorylation seems to take place
mainly in the axons of medium size spiny neurons and also in
a subset of ChAT-positive large interneurons.
Apoptosis detection in the striatum and cortex
of Tet/DN-GSK-3 mice
Since apoptosis of liver cells was the most prominent pheno-
type in GSK-3b knock-out mice (Hoeﬂich et al, 2000), we
wondered whether expression of DN-GSK-3 in neurons of
Tet/DN-GSK-3 mice might also result in apoptosis. In this
regard, although no obvious atrophy takes place in the brain
of Tet/DN-GSK-3 mice, in immunoﬂuorescence experiments
we observed that some myc-positive neurons showed frag-
mented nuclei (not shown). To explore in a quantitative
manner the incidence of neuronal apoptosis in the forebrain
of Tet/DN-GSK-3 mice, we performed cleaved caspase-3 and
TUNEL stainings. As anticipated, Tet/DN-GSK-3 mice showed
a marked increase in the number of cleaved caspase-3-
positive cells in the striatum (Figure 3B–D). Although de-
creased enzymatic activity was detected only in the striatum,
we also analyzed apoptosis in the other brain regions with
Figure 2 Decreased GSK-3 activity in Tet/DN-GSK-3 mice. (A) Western blot detection of GSK-3b, phosphorylated GSK-3 (pSer21/9 GSK-3a/b),
AT-8 and PHF-1 phospho-tau epitopes, and b-catenin levels in homogenates from striatum of Tet/DN-GSK-3 mice and wild-type (wt)
littermates. (B) In vitro GSK-3 activity assay performed on striatum, cortex, hippocampus and cerebellum homogenates from Tet/DN-GSK-3
mice and wt littermates (**Po0.001).
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robust transgene expression (cortex and hippocampus), be-
cause apoptosis might take place in speciﬁc neuronal sub-
populations that show relatively higher expression of the
transgene an/or that are particularly vulnerable to apoptosis
triggered by decreased GSK-3 activity. In fact, the number
of cleaved caspase-3 positive cells was also signiﬁcantly
increased in the cortex of Tet/DN-GSK-3 mice (Figure 3A
and D). As expected, this takes place in the external layers
(Figure 3A), where transgene expressing neurons are located
(see Figure 1E). No signiﬁcant difference in the number of
cleaved caspase-3-positive cells was detected in the hippo-
campus or in non-expressing regions such as cerebellum
(Figure 3D). Besides, we performed double immunoﬂuores-
cence experiments that conﬁrmed that caspase-3-positive
cells were also detected with anti b-gal (Figure 3E and F)
and with anti-Neu-N (not shown) antibodies, thus proving
that the detected dying cells are transgene expressing neu-
rons. Similar results were obtained with TUNEL staining
(Figure 3G and H).
Tet/DN-GSK-3 mice show reduced motor coordination
The striatum and the cerebral cortex, the brain regions where
increased apoptosis was detected in Tet/DN-GSK-3 mice, are
part of the basal ganglia circuit involved in motor control. For
this reason we decided to analyze Tet/DN-GSK-3 mice in
various tests of motor coordination. We ﬁrst analyzed the
Tet/DN-GSK-3 mice in the rotarod apparatus (Figure 4A–C).
After pretraining of mice at constant speed, the rotarod was
set to accelerate from 4 to 40 r.p.m. over 5min and mice were
tested four times at 1-h intervals. As shown in Figure 4A, Tet/
DN-GSK-3 mice showed a marked deﬁcit in the three ﬁrst
accelerating trials. On average, across the four tests, only
38.674.6% of Tet/DN-GSK-3 mice versus 58.874.1% of the
wild-type mice remained on rod when it reached maximal
speed (Figure 4B), and the total time on rod was 262.1712.2 s
for wild type and 187.66713.4 s for Tet/DN-GSK-3 mice
(Po0.007; Figure 4C). The motor coordination deﬁcit in
Tet/DN-GSK-3 mice was conﬁrmed in the vertical pole test
that measures the time needed to descend along a rough-
surfaced pole and detects striatal-dependent motor deﬁcits
(Matsuura et al, 1997). As shown in Figure 4D, Tet/DN-GSK-3
mice required almost double amount of time to descend as
compared with the wild-type mice (43.1579.44 versus
25.3673.62 s; Po0.03). We then performed analysis of stride
length in the footprint test. As shown, in Figure 4E, Tet/
DN-GSK-3 mice also showed a reduction in stride length
Figure 3 Apoptosis detection in striatum and cortex of Tet/DN-GSK-3 mice. (A–D) Immunohistochemical detection and quantiﬁcation of
cleaved caspase-3-positive cells. (A–C) Low-magniﬁcation pictures of showing cleaved caspase-3-positive cells (indicated by arrows) in cortex
(A), dorsal striatum (B) and ventral striatum (C) of a Tet/DN-GSK-3 mouse. (i–vi) Magniﬁcations of the cleaved caspase-3-positive cells shown
in panels (A–C). Scale bar in panel (A) corresponds to 200mm in panels (A–C). (D) Histogram showing the incidence of cleaved caspase-3
immunopositive cells in striatum, cortex, hippocampus and cerebellum of Tet/DN-GSK-3 mice and their wild-type (wt) littermates. Data are
presented as the mean7s.e.m. number of immunopositive cells per 7mm2 in a 30mm section (n¼ 9, *Po0.05). (E–F) Double labeling
immunoﬂuorescence with anti-cleaved caspase-3 (E) and anti-b-gal (F) antibodies in the striatum of a Tet/DN-GSK-3 mouse. Scale bar in panel
(E) corresponds to 10mm in panels (E and F). (G, H) TUNEL staining in the striatum of a wt (G) and of a Tet/DN-GSK-3 (H) mouse. Scale bar in
panel (G) corresponds to 80mm in panels (G, H); cc, corpus callosum; GP, globus pallidus; CPu, caudate putamen; ac, anterior commisure; NA,
nucleus accumbens; Tu, olfactory tubercle.
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(56.3170.87 versus 53.1771.07mm; Po0.03) and higher
maximal difference on stride length (23.5671.95 versus
28.8271.41mm; Po0.02), thus further demonstrating a def-
icit in motor coordination. Finally, to conﬁrm the speciﬁcity
of the observed motor coordination deﬁcit, we analyze the
general motor activity of Tet/DN-GSK-3 mice in the open ﬁeld
test (Figure 4A). Interestingly, no difference between control
and Tet/DN-GSK-3 mice was observed either during the ﬁrst
minute (transferal arousal) or in the rest of the testing
session.
Reduced dopamine-dependent behavior in
Tet/DN-GSK-3 mice
The motor deﬁcit in Tet/DN-GSK-3 mice might be explained
at least in part by the increased incidence of apoptosis in
basal ganglia regions, cortex and striatum. On the other hand,
dopamine (DA) neurotransmission from midbrain to the
striatum is a key determinant of the activity of striatal
neurons and, as a consequence, of motor behavior.
Interestingly, striatal GSK-3 activity has recently been
shown to be an important mediator of DA action on striatal
function and behavior (Beaulieu et al, 2004). It is therefore
possible that the observed motor deﬁcit also results from
decreased DA-dependent striatal function and behavior in
Tet/DN-GSK-3 mice. To explore whether Tet/DN-GSK-3 mice
indeed show reduced striatal activation and reduced motor
activity in response to DA, wild-type and Tet/DN-GSK-3 mice
were challenged with amphetamine to induce a classic
DA-dependent behavioral response. As shown in Figure 5A,
in vivo microdialysis revealed that systemic administration of
amphetamine (2.5mg/kg, i.p.) induced a similar increase in
extracellular DA levels in both groups of mice. Two-way
ANOVA revealed a signiﬁcant effect of amphetamine
(F1,15¼ 3.76, Po0.00002), but no signiﬁcant effect of geno-
type or genotype amphetamine interaction. The maximal
effect on striatal DA levels was 224741% of baseline in wild-
type mice and 229739% in transgenic mice. However,
despite equivalent striatal DA release, this amphetamine
challenge increased locomotor activity in wild-type but not
Tet/DN-GSK-3 mice (Figure 5B). In good agreement, the
amphetamine-induced expression of c-Fos (a marker of neu-
ronal activity) in striatum was markedly lower in Tet/DN-
GSK-3 (Figure 5C–F). Altogether, these results indicate that
(a) the dopaminergic (presynaptic) component of the nigros-
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footprint test. (F) Open ﬁeld locomotion test. The number of squares entered was counted during the 5min testing period. Performance in the
ﬁrst minute is also depicted to distinguish the effect of the transferal arousal from the total activity.
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triatal pathway is unaltered in Tet/DN-GSK-3 mice and (b) the
reduction of DA-dependent behaviors in transgenic mice can
be attributed to an attenuation of postsynaptic dopaminergic
signalling resulting from the stratial expression of DN-GSK-3.
Reversal of motor deﬁcit and of neuronal death
in doxycycline-treated Tet/DN-GSK-3 mice
Selective GSK-3 inhibitors are under development for the
treatment of chronic neurodegenerative and metabolic con-
ditions (Cohen and Goedert, 2004). However, the above
described toxicity for adult basal ganglia neurons elicited by
DN-GSK-3 expression suggests possible motor side effects if
selective GSK-3 inhibitors are given at excessive doses. This
prompted us to explore whether the neuronal apoptosis and
motor-deﬁcit phenotype was susceptible to revert upon ces-
sation of transgene expression by giving tetracyclines to
symptomatic Tet/DN-GSK-3 mice. For this, we ﬁrst veriﬁed
that doxycycline administration results in efﬁcient transgene
shut-down in Tet/DN-GSK-3 mice as a ﬁrst step before asses-
sing whether restoration of normal GSK-3 levels would also
result in normal GSK-3 activity. As expected, according to our
previous experience in shutting down transgene expression
in similar conditional mouse models (Yamamoto et al, 2000;
Diaz-Hernandez et al, 2005; Engel et al, 2006), 6 weeks of a
high dose of doxycycline (2mg/ml in the drinking water) or 4
months of a low dose (0.5mg/ml) led to undetectable levels
of the reporter transgene expression in treated (Gene-Off)
Tet/DN-GSK-3 mice (Figure 6A and B). Similarly, GSK-3b and
p-GSK-3 levels were no longer increased respect to non-
transgenic littermates (data not shown).
We then analyzed whether GSK-3 activity was susceptible
to return to normal levels after doxycycline treatment.
For this, untreated (Gene-On) and treated (Gene-Off) Tet/
DN-GSK-3 mice and their respective control littermates were
analyzed by in vitro GSK-3 enzymatic assays on striatal
homogenates. As shown in Figure 6C, Gene-Off Tet/DN-
GSK-3 mice showed signiﬁcantly increased GSK-3 activity
compared to Gene-On Tet/DN-GSK-3 mice and they were
indistinguishable from their control littermates. This demon-
strates that restoration of normal GSK-3 levels also results in
normal GSK-3 activity.
This prompted us to analyze whether restoration of normal
GSK-3 activity would also prevent the increased incidence
of neuronal apoptosis detected in Tet/DN-GSK-3 mice.
As shown in Figure 6D, the increase in the number of
cleaved caspase-3-positive neurons observed in gene-On
Tet/DN-GSK-3 mice was no longer detected in gene-Off Tet/
DN-GSK-3 mice.
Finally, the potential reversibility of the Tet/DN-GSK-3
mouse motor phenotype was also explored. As shown in
Figures 4A–C and 6E, 3-month-old Tet/DN-GSK-3 mice show
a motor deﬁcit in the rotarod apparatus. We then split the Tet/
DN-GSK-3 mice shown in Figure 6E and their respective
control littermates into two groups. One group was main-
tained without any pharmacological intervention and the
other was given doxycycline in the low-dose administration
paradigm (see Materials and methods) previously shown to
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efﬁciently stop transgene expression without affecting rotar-
od performance in control mice (Diaz-Hernandez et al, 2005).
Untreated (Gene-On) and treated (Gene-Off) Tet/DN-GSK-3
mice and their respective control littermates were then
retested every month in the accelerating rotarod test.
Despite a tendency for improved rotarod performance over
time after 1, 2 or 3 months of doxycycline treatment, this did
not reach statistical signiﬁcance (data not shown). However,
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as shown in Figure 6E, after 4 months, Gene-off Tet/DN-GSK-3
mice showed a signiﬁcantly better performance in rotarod
compared to Gene-on Tet/DN-GSK-3, and they were indis-
tinguishable from wild-type mice. Similarly, 6 weeks of 2mg/
ml doxycycline also resulted in reversal of the deﬁcit ob-
served in the vertical pole test and the average stride length
was no longer signiﬁcantly different between untreated
(Gene-On) and treated (Gene-Off) Tet/DN-GSK-3 mice
(Figure 6F and data not shown). Together, these results
suggest that potential motor side effects of excessive pharma-
cological GSK-3 inhibition might be susceptible to revert.
Discussion
By generating conditional transgenic mice with expression of
DN-GSK-3 in adult forebrain neurons, here we show that a
sustained reduction in GSK-3 activity is deleterious for striatal
and cortical neurons, as evidenced by histological detection
of apoptosis and by a concomitant deﬁcit in motor coordina-
tion. Interestingly, by shutting down DN-GSK-3 expression in
symptomatic mice, we found that both the motor-impairment
phenotype and the neuronal toxicity were susceptible to
revert upon restoration of normal GSK-3 activity.
Extensive data have proposed GSK-3 inhibitors as neuro-
protective and antiapoptotic agents (Frame and Cohen, 2001;
Grimes and Jope, 2001; Beurel and Jope, 2006). Supporting
reports explore many different apoptotic stimuli, including
trophic support withdrawal, PI3-kinase inhibition, DNA
damage, mitochondrial toxins, hypoxia/ischemia and glutamate
excitotoxicity, among others (Pap and Cooper, 1998; Hetman
et al, 2000; Beurel and Jope, 2006). However, decreased GSK-3
activity by disruption of the murine GSK-3b gene was also
known to result in embryonic lethality caused by massive
apoptosis in liver during mid-gestation (Hoeﬂich et al, 2000).
Our results of neuronal apoptosis in striatum and cortex
of Tet/DN-GSK-3 mice further conﬁrm that chronically
decreased GSK-3 activity compromises cell viability in vivo
and extends this ﬁnding to adult tissues and post-mitotic cells
such as neurons. In this regard, there is an apparent dis-
crepancy between the regional extent of GSK-3 inhibition and
of detection of apoptosis in Tet/DN-GSK-3 mice because
apoptosis is found in cortex, where no signiﬁcant decrease
of GSK-3 activity is detected by enzymatic assays or by Ser21/
9GSK-3 Western blot in cortical homogenates. This can be
explained by the fact that, in the cortex only a fraction of
neurons express the transgene. More precisely, expression is
restricted to certain neurons within layers I–III. It is in these
layers that increased apoptosis is detected by techniques with
cellular resolution (e.g. cleaved caspase-3 staining). However,
cortical homogenates for biochemical measurement of GSK-3
activity include layers IV–VI, as well as other non-expressing
cells in layers I–III. Therefore, enzymatic activity measure-
ments in cortical samples, despite showing a tendency to-
wards decreased activity, do not detect the inhibition in
speciﬁc transgene expressing neurons due to a dilution effect
of those neurons within the whole homogenate.
There are also some reports of GSK-3 inhibitor treatment
resulting in facilitation of apoptosis. More precisely, in apop-
tosis triggered in cultured cells by TNFa (Beyaert et al, 1989;
Hoeﬂich et al, 2000) or, including in neurons, by agonistic
anti-Fas antibodies (Song et al, 2004; Beurel and Jope, 2006).
Interestingly, an explanation for this paradoxical role of
GSK-3 activity and inhibition on apoptosis regulation has
recently been proposed (Beurel and Jope, 2006). It seems that
inhibition of GSK-3 activity facilitates apoptosis executed
through the extrinsic (involving stimulation of death domain
containing receptors) pathway, but prevents apoptosis execu-
tion if it is elicited through the intrinsic (mitochondria
mediated) pathway. In view of this, it is therefore likely
that embryonic hepatocytes and adult cortical and striatal
neurons have in common a tonic inﬂuence of extracellular
signals able to stimulate death domain containing receptors
leading to a situation in which intact GSK-3 activity would be
required to prevent apoptosis execution.
The results reported here are indicative of the effects of
sustained GSK-3 inhibition and, to some extent, they may
have implications when considering the potential side effects
and the potential therapeutic efﬁcacy of chronic administra-
tion of the potent and selective GSK-3 inhibitors that are
currently under development for treatment of chronic condi-
tions such as Alzheimer’s disease, mood disorders and dia-
betes (Cohen and Goedert, 2004; Frame and Zheleva, 2006;
Gould et al, 2006). However, it should also be noticed that
drug administration can vary greatly from genetic inhibition
in terms of the efﬁcacy, retention and clearance and the
speciﬁcity of treatments. Regarding possible side effects, as
above mentioned, one of the a priori concerns is the tumori-
genic potential of chronic GSK-3 inhibition (Polakis, 2000). In
this regard, we did not ﬁnd any evidence of tumor formation
in Tet/DN-GSK-3 mice. However, this is not surprising, since
transgene expression in these mice is restricted to neurons
that are post-mitotic cells. Breeding DN-GSK-3 mice with
driver mice expressing tTA under control of broader expres-
sion promoters will give a more comprehensive view of the
tumorigenesis risk. Apoptosis, the other predicted potential
side effect, is conﬁrmed in neurons of Tet/DN-GSK-3 mice
and therefore suggests potential neurological consequences
of chronic GSK-3 inhibitor administration that are further
supported by the motor phenotype. However, since the
rational for using GSK-3 inhibitors arises from the concept
of aberrantly increased GSK-3 activity contributing to the
etiology of various disorders, it is likely that these inhibitors
will prove effective and safe if they are given to a dose that
decreases GSK-3 activity without lowering it beyond its
normal level.
Regarding the value of Tet/DN-GSK-3 mice in predicting the
therapeutic potential of inhibitors, this can be explored by
combining these mice with animal models of the various
related disorders. In the case of Alzheimer’s disease, GSK-3
has been linked to b-amyloid (Ab) production from its pre-
cursor APP (Sun et al, 2002; Phiel et al, 2003; Ryder et al,
2003), to mediate Ab-induced toxicity (Takashima et al, 1993;
Alvarez et al, 1999), to contribute to mutant Presenilin-1 (PS-1)
toxicity (Takashima et al, 1998), and to tau hyperphosphor-
ylation (Hanger et al, 1992; Lovestone et al, 1994). Since Tet/
DN-GSK-3 mice express the transgene in neurons of the brain
regions affected in Alzheimer’s disease, it would be interest-
ing to combine them with any of the many available mouse
models of Alzheimer’s disease including those with modiﬁed
expression of APP, PS-1, tau (Lim et al, 2001; Wong et al,
2002), or combinations of these (Engel et al, 2005).
If neuropathology and/or learning deﬁcit improve in the
mice resulting from combining Alzheimer’s disease models
with Tet/DN-GSK-3 mice, this would strongly support the
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therapeutic potential of GSK-3 inhibitors for this disease.
However, to be predictive of the potential of GSK-3 inhibitors
to treat metabolic disorders like diabetes, Tet/DN-GSK-3 mice
should be generated with muscle and/or liver promoters to
then be combined with chemical or transgenic models of
diabetes.
The observed reduction in DA-dependent striatal induction
of c-Fos and locomotor behavior in Tet/DN-GSK-3 mice ﬁts
well with the previously reported role of GSK-3 as an
important mediator of DA actions in the striatum (Beaulieu
et al, 2004). This, together with the here reported importance
of intact GSK-3 activity for cortical and striatal neuron
viability, may explain not only the motor deﬁcit observed in
Tet/DN-GSK-3 mice but also the tremor that appears as the
most prominent motor side effect of the therapy of bipolar
disorder with lithium, a well established GSK-3 inhibitor
(Klein and Melton, 1996; Macritchie and Young, 2004).
In summary, the here reported generation and character-
ization of conditional transgenic mice with postnatal neuron
expression of DN-GSK-3 revealed a key role of GSK-3 in adult
neuron physiology and viability, and warns of potential
neurological side effects of chronic administration of GSK-3
inhibitors. Interestingly, the reported reversibility data
strongly support that such unwanted side effects are likely
to revert if excessive GSK-3 inhibition is halted. Besides, the
future combination of these DN-GSK-3 mice with mouse
models of the various diseases linked to increased GSK-3
activity will help to elucidate the therapeutic potential of
GSK-3 inhibitor therapies for each of these diseases.
Materials and methods
The Materials and methods are only described very brieﬂy. For
further information, see the Supplementary data section.
Generation of Tet/DN-GSK-3 mice
To generate Tet/DN-GSK-3bmice, wild-type GSK-3b sequence in the
pBI-G-GSK-3 plasmid (Lucas et al, 2001) was replaced by the K85R-
GSK-3b sequence from the XGSK3b-R85 plasmid (Munoz-Montano
et al, 1999). The transgene fragment was microinjected into single
cell FVB/N embryos. Four founder, mice were identiﬁed by PCR and
each founder line was ampliﬁed by backcrossing with wild-type
FVB/N mice. The CamkII-tTa mouse line (Mayford et al, 1996) is
maintained in a mixed CBAxC57BL/6 background.
Doxycycline treatment
Tet/DN-GSK-3b mice and their control littermates were given
doxycycline (Sigma) (2mg/ml) in drinking water ad libitum for
6 weeks. We have previously shown that this paradigm results in
complete shut-down of the transgene in a similar conditional mouse
model that overexpresses wild-type GSK-3 (Lucas et al, 2001; Engel
et al, 2006). To explore reversal of rotarod phenotype, doxycycline
was given at 2mg/ml for 1 week, 1mg/ml for a second week and
0.5mg/ml the rest of the treatment session up to 4 months. This
paradigm also results in complete transgene shut-down in Tet/
DN-GSK-3b mice, without worsening rotarod performance in wild-
type mice (Diaz-Hernandez et al, 2005).
Immunohistochemistry and immunoﬂuorescence
Brains were ﬁxed in 4% paraformaldehyde in PBS and cryopro-
tected. Sagittal sections were pretreated for 30min in 1% H2O2/
PBS, followed by 1 h with 1% BSA, 5% FBS and 0.2% Triton X-100,
incubated overnight with primary antibody and developed with the
Elite Vectastain kit (Vector Laboratories) using diaminobenzidine
(Sigma) and 0.003% H2O2. For immunoﬂuorescence, after treat-
ment with primary antibody, the sections were washed in PBS and
incubated with the following secondary antibodies: goat anti-rabbit
Alexa 488 (Invitrogen) and goat anti-mouse Alexa 594 (Invitrogen).
Nuclei were stained by using DAPI (1:5000, Calbiochem).
TUNEL assay
Mice were anesthetized and transcardially perfused with 4% PFA in
PBS for 10min. Brains were post-ﬁxed in 4% PFA for 2 h at 41C and
cryoprotected. Sections were treated following the protocol of the
In Situ Cell Death Detection Kit, POD (Roche).
Western blot analysis
The protocols are described in detail in the Supplementary data
section.
GSK-3 activity assay
Tissue was homogenized in 20mM HEPES, pH 7.4, 100mM NaCl,
10mM NaF, 1mM VO4Na, 1% Triton 100-X, 1mM EDTA, 1mM
EGTA and a cocktail of peptidase inhibitors (Roche). Supernatants
were collected after centrifugation at 14 000 g for 15min. The GS1
peptide (YRRAAVPPSPSLSRHSSPHQS*EDEE) with phosphorylated
ser21 was used as substrate (Stambolic and Woodgett, 1994).
Supernatants were incubated at 371C with GS1 peptide and
[g-32P]ATP in 25mM Tris–HCl pH 7.5, 1mM DTT 10mM MgCl2
and either 20mM NaCl or 20mM LiCl. The assays were stopped by
spotting aliquots on P81 phosphocellulose as described (Engel et al,
2006).
Behavioral testing
Open ﬁeld locomotion:Major locomotor activity was tested as in the
SHIRPA protocol (Rogers et al, 1997). Brieﬂy, the arena (55
3318 cm) is divided in equally-dimensioned squares (about
11 cm). Locomotion activity (as number of square entered with all
the four paws) is counted during 5min.
Rotarod test was performed with accelerating rotarod apparatus
(Ugo Basile, Comerio, Italy). Mice were pretrained during 2 days.
Then, the rotarod was set to accelerate from 4 to 40 r.p.m. over
5min and mice were tested four times. During accelerating trials,
the latency to fall from the rotarod was measured.
Vertical pole test was performed as described (Matsuura et al,
1997). The mouse was placed head-upward on the top of a vertical
rough-surfaced pole (diameter 1 cm; height 50 cm) and the time
until it descended to the ﬂoor was recorded, with a maximum
duration of 120 s.
Footprint pattern test was performed as described (Barlow et al,
1996). The back paws of each mouse were dipped into ink and it
was placed at the entrance of a dark tunnel (9.2 6.3 35.5 cm).
The footprints were recorded on paper. Stride lengths were
determined by measuring the distance between each step on the
same side of the body.
In vivo microdialysis
Microdialysis was performed as described (Dı´az-Mataix et al, 2005).
Anesthetized mice were stereotaxically implanted with microdia-
lysis probes in the striatum at the following coordinates
(in millimeters): APþ 0.5, L 1.7, DV 4.5, according to the
mouse atlas of Franklin and Paxinos (1997). Microdialysis was
performedB20h after surgery. Probes were perfused with artiﬁcial
cerebrospinal ﬂuid. Dialysates were collected every 20min. After a
100min stabilization, four fractions were collected for basal values
before systemic administration of amphetamine. Then, dialysis
samples were collected. The DA concentration in dialysates was
determined by HPLC.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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